‘Barron’s Roundtable’ panelists discuss the hefty cost of obesity drugs and its impact on Medicare benefits.
AstraZeneca moved on Thursday to boost its drugs pipeline in the booming anti-obesity market, saying it would pay China’s Eccogene up to about $2 billion for an exclusive license to develop an experimental oral drug in the field.
The Anglo-Swedish drugmaker said it had struck the deal for ECC5004, a once-daily oral drug that is part of a class of highly promising weight-loss medicines known as GLP-1 receptor agonists currently dominated by Novo Nordisk and Eli Lilly, which have injectable products.
FDA APPROVES ELI LILLY’S TIRZEPATIDE FOR WEIGHT LOSS
Astra, alongside reporting quarterly results, said Eccogene would receive $185 million up front, plus up to $1.825 billion depending on certain clinical, regulatory, and commercial achievements. Astra also agreed to pay tiered royalties on sales.
FOX Business’ Charles Payne, Gerri Willis and Lydia Hu react to young people using laxatives to lose weight on ‘Making Money.’
The London-listed drugmaker said the compound had shown promise in the first of three phases of testing on humans and ECC5004 would be further developed to treat obesity, type-2 diabetes and other cardiometabolic conditions.
ELI LILLY, NOVO NORDISK TEST POPULAR WEIGHT LOSS-RELATED DRUGS ON CHILDREN
It added that ECC5004 is a small molecule compound, meaning it can be more easily produced than the complex injectable peptides that are the basis of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound, also known as Mounjaro or tirzepatide.
Jack Hough and the panel discuss a new drug aimed at tackling obesity and the possible other benefits the drug may have on ‘Barron’s Roundtable.’
U.S. and UK regulators both gave the thumbs up to Lilly’s Zepbound on Wednesday, paving the way for a powerful new rival to Novo’s Wegovy in addressing record obesity rates.
SEEING MORE WEIGHT-LOSS DRUG ADS? HERE’S WHY
Astra has already entered the race for a next generation of weight-loss drugs. Also in the first phase of clinical trials, it has been testing a potential obesity drug based on the gastrointestinal hormone amylin as well as a once-weekly injection that is based on two modes of action including GLP-1.
AstraZeneca
